Litcius/Paper detail

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

Tsukasa Hasegawa, Ryo Ariyasu, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Atsushi Horiike, Toshio Sakatani, Takehiro Tozuka, Jun Shiihara, Masafumi Saiki, Yuichi Tambo, Tomoaki Sonoda, Akito Miyazaki, Shinya Uematsu, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishino

2023Cancer Chemotherapy and Pharmacology12 citationsDOI

Topics & Concepts

DurvalumabDiscontinuationMedicineChemoradiotherapyInternal medicineOncologyLung cancerProgressive diseaseChemotherapyCancerImmunotherapyPembrolizumabLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02) | Litcius